Disulfiram

Disulfiram (Tetraethylthiuram disulfide) is a specific inhibitor of aldehyde-dehydrogenase (ALDH1), used for the treatment of chronic alcoholism by producing an acute sensitivity to alcohol. Disulfiram inhibits gasdermin D (GSDMD) pore formation in liposomes and inflammasome-mediated pyroptosis and IL-1β secretion in human and mouse cells. Disulfiram, a copper ion carrier, with Cu2+ increases intracellular ROS levels and induces cuproptosis[1][2][3][4][5][6].

97-77-8

Tetraethylthiuram disulfide; TETD

12352211

H302, H317, H373, H410

Aldehyde Dehydrogenase (ALDH) ; Apoptosis; Cuproptosis; Interleukin Related; Pyroptosis

Reference compound

Apoptosis; Immunology/Inflammation; Metabolic Enzyme/Protease

Cancer-programmed cell death

Metabolic Disease; Cancer

https://www.medchemexpress.com/disulfiram.html

99.92

DMSO : 75 mg/mL (ultrasonic)

S=C(SSC(N(CC)CC)=S)N(CC)CC

C10H20N2S4

296.54

H302, H317, H373, H410

[1]Chen D, ert al. Disulfiram, a clinically used anti-alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and?xenografts?via?inhibition?of the proteasome?activity. Cancer Res. 2006 Nov 1;66 (21) :10425-33.|[2]Wang W, et al. Disulfiram-mediated inhibition of NF-kappaB activity enhances cytotoxicity of 5-fluorouracil in human colorectal cancer cell lines. Int J Cancer. 2003 Apr 20;104 (4) :504-11.|[3]Cen D, et al. Disulfiram facilitates intracellular Cu uptake and induces apoptosis in human melanoma cells. J Med Chem. 2004 Dec 30;47 (27) :6914-20.|[4]Brar SS, et al. Disulfiram inhibits activating transcription factor/cyclic AMP-responsive element binding protein and human melanoma growth in a metal-dependent manner in vitro, in mice and in a patient with metastatic disease. Mol Cancer Ther. 2004 Sep;3|[5]Jun Jacob Hu, et al. Identification of pyroptosis inhibitors that target a reactive cysteine in gasdermin D. The Preprint Server For Biology, 2018, Jul. 10.|[6]Guo F, et, al. Inhibitory effect on ovarian cancer ALDH+ stem-like cells by Disulfiram and Copper treatment through ALDH and ROS modulation. Biomed Pharmacother. 2019 Oct;118:109371.

Room Temperature

-20°C, 3 years; 4°C, 2 years (Powder)

Reference compound1

Launched